Committee Composition

Arie Belldegrun M.D., FACS

Dr. Belldegrun has been closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. In 1996 he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman of the board of directors and as a board member until 2007, when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009 when it was acquired by Johnson & Johnson. He currently serves as Chairman of Arno Therapeutics, Inc., Two River Group, and TheraCoat Ltd., and as a board member of SonaCare Medical, LLC and Teva Pharmaceutical Industries Ltd. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/NIH, as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at Harvard Medical School. He has authored several books in Oncology and more than 400 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons (AAGUS).

David Bonderman is a founding partner of TPG, one of the world’s largest private equity investment firms. TPG generally makes significant investments in operating companies through acquisitions and restructurings across a broad range of industries throughout the United States, Europe and Asia.

Prior to forming TPG in 1992, Mr. Bonderman was Chief Operating Officer of the Robert M. Bass Group, Inc. (now doing business as Keystone Group, L.P.) in Fort Worth, Texas. Prior to joining RMBG in 1983, Mr. Bonderman was a partner in the law firm of Arnold & Porter in Washington, D.C., where he specialized in corporate, securities, bankruptcy and antitrust litigation. From 1969 to 1970, Mr. Bonderman was a Fellow in Foreign and Comparative Law in conjunction with Harvard University, and from 1968 to 1969, he was Special Assistant to the U.S. Attorney General in the Civil Rights Division. From 1967 to 1968, Mr. Bonderman was Assistant Professor at Tulane University School of Law in New Orleans.

Mr. Bonderman graduated magna cum laude from Harvard Law School in 1966. He was a member of the Harvard Law Review and a Sheldon Fellow. He is a 1963 graduate of the University of Washington in Seattle. In addition to serving on the board of directors of several private and public companies, Mr. Bonderman also serves on the boards of The Wilderness Society, the Grand Canyon Trust, The University of Washington Foundation and the American Himalayan Foundation.

Member of the Commercialization Committee
Chair of the Commercialization Committee

Farah Champsi is a Managing Director at Alta Partners. She also currently serves on the board of directors of Chimerix, Trevena and Allakos. Prior to joining Alta in 2000, Ms. Champsi was an investment banker at Robertson Stephens & Company where she focused on biotechnology and other life sciences companies. She was elected a General Partner in 1992 and head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street. She holds a Master of Business Administration from Stanford University and a Bachelor of Arts in Economics from Smith College.

Roy Doumani is Executive Director of the Business of Science Center and a professor at the David Geffen School of Medicine at UCLA teaching “The Business of Science”, “Advancing Bioengineering Innovations”, and “Healthcare Technology” to graduate students. He currently serves as Co-Chairman of the Zhejiang California NanoSystems Institute in the People’s Republic of China.

With a background in international finance and banking, Roy holds an equity position in and served as Vice Chairman of the first joint venture bank in the PRC, Xiamen International Bank and has been involved with numerous financial institutions: Founder and Director of First Los Angeles Bank; Chairman of First Interstate Bank of Hawaii; Director of HonFed Bank; one of the Founders of Agensys, Inc.; Investor and Board Member of Kite Pharma; Chairman of World Trade Bank in Los Angeles. Roy has served as a board member and advisor to companies in the United States, Asia, Europe and the Middle East.

Roy is a member of RAND’s Center for Asia Pacific Policy’s advisory board and Chairman of the Pacific Pension Institute’s advisory board. He has established endowed chairs at UCLA, in the Departments of Medical and Molecular Pharmacology and Urological Oncology. Roy is also a Trustee at the Norton Simon Museum.

Roy Doumani graduated from the University of California at Los Angeles (UCLA) with a degree in Business and Finance and received a law degree from the University of Southern California.

Member of the International Strategy Committee

Franz Humer, an Austrian by birth, born 1946 and holder of Austrian and Swiss passports. He was educated at the University of Innsbruck where he gained a PhD in Law. He then went on to obtain an MBA at INSEAD in Fontainebleau.

In 1971, Franz Humer became a Management Consultant in Zurich before joining Schering Plough Inc in 1973, where he held several positions including General Manager for various Latin American and European countries.

He joined Glaxo Holdings in 1981 and was appointed Managing Director of Glaxo Pharmaceuticals UK Ltd in 1987. In 1989 he was elected to the Board of Glaxo Holdings plc and in 1992 became Chief Operating Director for Glaxo's worldwide operations (excluding USA).

Dr. Humer joined Hoffmann-La Roche in 1995 as Head of the Pharmaceuticals Division and Member of the Board. He was appointed Chief Operating Officer in 1996, Chief Executive Officer in 1998 and in April 2001 he was appointed Chairman of the Board of Directors and Chief Executive Officer. From March 2008 to March 2014 he has been Chairman of the Board of Directors of Roche Holding Ltd.

In July 2006, he was awarded from the Republic of Austria “Grosses goldenes Ehrenzeichen mit dem Stern für Verdienste um die Republik Oesterreich”. In the same year he became an Honorary Doctor of the University of Basel. He also holds an honorary doctorate from the School of Pharmacy, University of London. In 2013 he was awarded the Singapore Public Service Star (Distinguished Friends of Singapore).

Franz Humer joined the Board of Diageo, the world’s leading spirits company, in 2005 and became its Chairman in 2008. He is also Chairman of the Board of Directors of the International Centre for Missing and Exploited Children and the Humer Foundation. He is an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd (Japan), Bial Pharmaceuticals (Portugal), Kite Pharma (Biotech company in Los Angeles), WISeKey (Cyber Security Company, Switzerland) and a member of the International Advisory Board of Allianz SE.

Chair of the International Strategy Committee

Joshua Kazam is a director and co-founder of Kite, which was incorporated in 2009 by Two River, a New York merchant bank that focuses on the life science sector. Mr. Kazam is a co-founder and managing member of Two River. Prior to Two River, Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a New York based private equity fund focused on biotechnology investments. Mr. Kazam is a member of the Board of Directors of Capricor Therapeutics (NASD:CAPR), Tranzutary Holdings LLC and also serves as an Officer and Director of Riverbank Capital Securities, Inc., a FINRA member broker dealer. Mr. Kazam holds a BsC in Economics from Wharton School of the University of Pennsylvania, and currently resides in New York City.

Ran Nussbaum is a managing partner and the co-founder of The Pontifax Group, who has established three funds with over $220M under management and over 30 portfolio companies. Over the past ten years, Mr. Nussbaum has been managing the group's activity alongside Mr. Tomer Kariv. He also served as CEO of Biomedix and Spearhead Ltd. as well as Ocon chairman of the board.

Mr. Nussbaum’s real life experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Mr. Nussbaum serves as a board member of many of the group's portfolio companies including, c-CAM, Insuline (public co.), Eloxx, Bioblast, TheraCoat, CollPlant (public), Protab, Quiet, Fusimab Ltd and Ocon.

Jon Peacock was chief financial officer of Amgen from 2010 to 2014. In this role, he was responsible for finance, investor relations, strategy, corporate development and procurement.

Prior to Amgen Mr. Peacock served as chief financial and administration officer for Novartis Pharmaceutical AG since 2005. He was responsible for Finance, strategic planning, mergers and acquisitions, IT and procurement. In addition, Mr. Peacock was responsible for Novartis’ malaria program, a corporate citizenship initiative in conjunction with the major donor organizations, to supply the company’s malaria medicine at cost to countries throughout Africa.

Previously, Mr. Peacock was a partner at McKinsey and Company, working for the consulting firm’s Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St. Andrews in Scotland and is a chartered accountant.

Member of the Commercialization Committee

Mr. Ruchefsky is President of Commercial Street Capital LLC, a private investment company and significant stockholder in Kite Pharma. For the last decade, Mr. Ruchefsky has been working as a private investment manager for the founder and CEO of a multi-billion dollar hedge fund. Mr. Ruchefsky began his career at a prominent New York City law firm where he became a partner, member of management and chair of a specialized litigation group. Upon leaving his law firm and prior to his current employment, Mr. Ruchefsky was a principal of an early stage venture capital operation. Mr. Ruchefsky currently sits on the boards of several public and private companies, including Arno Therapeutics Inc., MD Solar Sciences and Energy Pioneer Solutions.

Mr. Ruchefsky is a graduate of The George Washington University Law School.

  Audit Nominating and Governance Compensation International Strategy Commercialization
David Bonderman
David Bonderman

David Bonderman is a founding partner of TPG, one of the world’s largest private equity investment firms. TPG generally makes significant investments in operating companies through acquisitions and restructurings across a broad range of industries throughout the United States, Europe and Asia.

Prior to forming TPG in 1992, Mr. Bonderman was Chief Operating Officer of the Robert M. Bass Group, Inc. (now doing business as Keystone Group, L.P.) in Fort Worth, Texas. Prior to joining RMBG in 1983, Mr. Bonderman was a partner in the law firm of Arnold & Porter in Washington, D.C., where he specialized in corporate, securities, bankruptcy and antitrust litigation. From 1969 to 1970, Mr. Bonderman was a Fellow in Foreign and Comparative Law in conjunction with Harvard University, and from 1968 to 1969, he was Special Assistant to the U.S. Attorney General in the Civil Rights Division. From 1967 to 1968, Mr. Bonderman was Assistant Professor at Tulane University School of Law in New Orleans.

Mr. Bonderman graduated magna cum laude from Harvard Law School in 1966. He was a member of the Harvard Law Review and a Sheldon Fellow. He is a 1963 graduate of the University of Washington in Seattle. In addition to serving on the board of directors of several private and public companies, Mr. Bonderman also serves on the boards of The Wilderness Society, the Grand Canyon Trust, The University of Washington Foundation and the American Himalayan Foundation.

     
Ian Clark      
Farah Champsi
Farah Champsi

Farah Champsi is a Managing Director at Alta Partners. She also currently serves on the board of directors of Chimerix, Trevena and Allakos. Prior to joining Alta in 2000, Ms. Champsi was an investment banker at Robertson Stephens & Company where she focused on biotechnology and other life sciences companies. She was elected a General Partner in 1992 and head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street. She holds a Master of Business Administration from Stanford University and a Bachelor of Arts in Economics from Smith College.

       
Roy Doumani
Roy Doumani

Roy Doumani is Executive Director of the Business of Science Center and a professor at the David Geffen School of Medicine at UCLA teaching “The Business of Science”, “Advancing Bioengineering Innovations”, and “Healthcare Technology” to graduate students. He currently serves as Co-Chairman of the Zhejiang California NanoSystems Institute in the People’s Republic of China.

With a background in international finance and banking, Roy holds an equity position in and served as Vice Chairman of the first joint venture bank in the PRC, Xiamen International Bank and has been involved with numerous financial institutions: Founder and Director of First Los Angeles Bank; Chairman of First Interstate Bank of Hawaii; Director of HonFed Bank; one of the Founders of Agensys, Inc.; Investor and Board Member of Kite Pharma; Chairman of World Trade Bank in Los Angeles. Roy has served as a board member and advisor to companies in the United States, Asia, Europe and the Middle East.

Roy is a member of RAND’s Center for Asia Pacific Policy’s advisory board and Chairman of the Pacific Pension Institute’s advisory board. He has established endowed chairs at UCLA, in the Departments of Medical and Molecular Pharmacology and Urological Oncology. Roy is also a Trustee at the Norton Simon Museum.

Roy Doumani graduated from the University of California at Los Angeles (UCLA) with a degree in Business and Finance and received a law degree from the University of Southern California.

     
Franz B. Humer
Franz B. Humer

Franz Humer, an Austrian by birth, born 1946 and holder of Austrian and Swiss passports. He was educated at the University of Innsbruck where he gained a PhD in Law. He then went on to obtain an MBA at INSEAD in Fontainebleau.

In 1971, Franz Humer became a Management Consultant in Zurich before joining Schering Plough Inc in 1973, where he held several positions including General Manager for various Latin American and European countries.

He joined Glaxo Holdings in 1981 and was appointed Managing Director of Glaxo Pharmaceuticals UK Ltd in 1987. In 1989 he was elected to the Board of Glaxo Holdings plc and in 1992 became Chief Operating Director for Glaxo's worldwide operations (excluding USA).

Dr. Humer joined Hoffmann-La Roche in 1995 as Head of the Pharmaceuticals Division and Member of the Board. He was appointed Chief Operating Officer in 1996, Chief Executive Officer in 1998 and in April 2001 he was appointed Chairman of the Board of Directors and Chief Executive Officer. From March 2008 to March 2014 he has been Chairman of the Board of Directors of Roche Holding Ltd.

In July 2006, he was awarded from the Republic of Austria “Grosses goldenes Ehrenzeichen mit dem Stern für Verdienste um die Republik Oesterreich”. In the same year he became an Honorary Doctor of the University of Basel. He also holds an honorary doctorate from the School of Pharmacy, University of London. In 2013 he was awarded the Singapore Public Service Star (Distinguished Friends of Singapore).

Franz Humer joined the Board of Diageo, the world’s leading spirits company, in 2005 and became its Chairman in 2008. He is also Chairman of the Board of Directors of the International Centre for Missing and Exploited Children and the Humer Foundation. He is an Independent Director with Citigroup Inc., Chugai Pharmaceuticals Ltd (Japan), Bial Pharmaceuticals (Portugal), Kite Pharma (Biotech company in Los Angeles), WISeKey (Cyber Security Company, Switzerland) and a member of the International Advisory Board of Allianz SE.

   
Joshua A. Kazam
Joshua A. Kazam

Joshua Kazam is a director and co-founder of Kite, which was incorporated in 2009 by Two River, a New York merchant bank that focuses on the life science sector. Mr. Kazam is a co-founder and managing member of Two River. Prior to Two River, Mr. Kazam served as the Director of Investment Management for the Orion Biomedical Fund, a New York based private equity fund focused on biotechnology investments. Mr. Kazam is a member of the Board of Directors of Capricor Therapeutics (NASD:CAPR), Tranzutary Holdings LLC and also serves as an Officer and Director of Riverbank Capital Securities, Inc., a FINRA member broker dealer. Mr. Kazam holds a BsC in Economics from Wharton School of the University of Pennsylvania, and currently resides in New York City.

         
Ran Nussbaum
Ran Nussbaum

Ran Nussbaum is a managing partner and the co-founder of The Pontifax Group, who has established three funds with over $220M under management and over 30 portfolio companies. Over the past ten years, Mr. Nussbaum has been managing the group's activity alongside Mr. Tomer Kariv. He also served as CEO of Biomedix and Spearhead Ltd. as well as Ocon chairman of the board.

Mr. Nussbaum’s real life experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Mr. Nussbaum serves as a board member of many of the group's portfolio companies including, c-CAM, Insuline (public co.), Eloxx, Bioblast, TheraCoat, CollPlant (public), Protab, Quiet, Fusimab Ltd and Ocon.

         
Jon Peacock
Jon Peacock

Jon Peacock was chief financial officer of Amgen from 2010 to 2014. In this role, he was responsible for finance, investor relations, strategy, corporate development and procurement.

Prior to Amgen Mr. Peacock served as chief financial and administration officer for Novartis Pharmaceutical AG since 2005. He was responsible for Finance, strategic planning, mergers and acquisitions, IT and procurement. In addition, Mr. Peacock was responsible for Novartis’ malaria program, a corporate citizenship initiative in conjunction with the major donor organizations, to supply the company’s malaria medicine at cost to countries throughout Africa.

Previously, Mr. Peacock was a partner at McKinsey and Company, working for the consulting firm’s Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St. Andrews in Scotland and is a chartered accountant.

     
Steven B. Ruchefsky
Steven B. Ruchefsky

Mr. Ruchefsky is President of Commercial Street Capital LLC, a private investment company and significant stockholder in Kite Pharma. For the last decade, Mr. Ruchefsky has been working as a private investment manager for the founder and CEO of a multi-billion dollar hedge fund. Mr. Ruchefsky began his career at a prominent New York City law firm where he became a partner, member of management and chair of a specialized litigation group. Upon leaving his law firm and prior to his current employment, Mr. Ruchefsky was a principal of an early stage venture capital operation. Mr. Ruchefsky currently sits on the boards of several public and private companies, including Arno Therapeutics Inc., MD Solar Sciences and Energy Pioneer Solutions.

Mr. Ruchefsky is a graduate of The George Washington University Law School.

     
= Chair = Member